echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > WuXi Biologics and ImmuneOncia of South Korea signed a memorandum of understanding for the development and production of anti-PD-L1/CD47 bispecific antibodies

    WuXi Biologics and ImmuneOncia of South Korea signed a memorandum of understanding for the development and production of anti-PD-L1/CD47 bispecific antibodies

    • Last Update: 2022-01-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    <>


    According to the memorandum of cooperation, ImmuneOncia will promote the development of this innovative bispecific antibody through WuXi Biologics' end-to-end services in cell line development, cell culture process development, biologics production, and bioassay method development .


    Mr.


    Dr.


    About ImmuneOncia

    ImmuneOncia is a biopharmaceutical company focusing on the field of tumor immunity


    About WuXi Biologics

    WuXi Biologics (stock code: 2269.


    As of June 30, 2021, 408 comprehensive projects have been developed on WuXi Biologics platform, including 212 in preclinical research phase, 160 in early clinical (phase I/II) phase, and 32 in late clinical phase ( Phase III) and 4 are in the commercial production stage


    WuXi Biologics regards environment, society and governance (ESG) as an important part of business development and corporate spirit, and is committed to becoming a global ESG leader in the field of biopharmaceuticals


    For more information, please contact:

    Media Relations


    Investor Relations


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.